Tonix Pharmaceuticals Holding CORP. (TNXP) — 10-Q Filings

All 10-Q filings from Tonix Pharmaceuticals Holding CORP.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (3)

Tonix Pharma's Losses Widen Amid Tonmya Launch Prep, Cash Reserves Grow — Nov 10, 2025 Risk: high
Tonix Pharmaceuticals Holding Corp. (TNXP) reported a net loss of $32.01 million for the three months ended September 30, 2025, a significant increase from the
Tonix Pharma's Q2 Loss Widens to $19.5M Amid Soaring R&D Costs — Aug 11, 2025 Risk: high
Tonix Pharmaceuticals Holding Corp. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company
Tonix Pharmaceuticals Files Q1 2025 10-Q — May 12, 2025 Risk: medium
Tonix Pharmaceuticals Holding Corp. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the first quarter of 2025, d

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX